SC interferon beta-1a
Showing 1 - 25 of >10,000
Female Participants Exposed to Subcutaneous Peginterferon
Completed
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Interferon Beta Therapy
-
Göttingen, GermanyResearch Site
Nov 1, 2021
Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
Completed
- Relapsing Multiple Sclerosis (RMS)
- Rebif (Interferon beta-1a)
-
Alger, Algeria
- +40 more
Mar 22, 2022
Multiple Sclerosis Trial in Cairo (Blood sample collection)
Recruiting
- Multiple Sclerosis
- Blood sample collection
-
Cairo, EgyptNasser Institute for Research and Treatment
Feb 21, 2023
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial
Not yet recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +5 more
- Interferon Beta-1A
- +10 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 6, 2023
Relapsing Multiple Sclerosis Trial in Worldwide (Interferon beta-1a, Ocrelizumab-matching , Ocrelizumab)
Active, not recruiting
- Relapsing Multiple Sclerosis
- Interferon beta-1a
- +3 more
-
Phoenix, Arizona
- +140 more
Jan 2, 2023
Multiple Sclerosis Trial in Shreveport (Interferon beta 1a, oral doxycycline)
Completed
- Multiple Sclerosis
- Interferon beta 1a, oral doxycycline
-
Shreveport, LouisianaLSU Health Sciences Center Shreveport
Oct 11, 2022
Healthy Subjects, Pharmacokinetics, Pharmacodynamics Trial in West Bend (Interferon beta-1a, Peginterferon beta-1a, Placebo)
Completed
- Healthy Subjects
- +2 more
- Interferon beta-1a
- +2 more
-
West Bend, WisconsinSpaulding Clinical Research
Aug 16, 2021
Relapsing Remitting Multiple Sclerosis (RRMS) Trial in Tehran (Pegylated interferon beta-1a, Interferon Beta-1A Prefilled
Active, not recruiting
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Pegylated interferon beta-1a
- Interferon Beta-1A Prefilled Syringe
-
Tehran, Iran, Islamic Republic ofSina Hospital
Feb 5, 2022
Learn About Interferon-beta Exposure of Pregnant Women During
Not yet recruiting
- Multiple Sclerosis (MS)
- Avonex (IFNβ-1-a, Biogen Netherlands B.V)
- +5 more
-
Multiple Locations, Finland
- +1 more
Sep 19, 2023
Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7 Trial in Seattle (drug, other, biological, radiation)
Terminated
- Merkel Cell Polyomavirus Infection
- Stage IV Merkel Cell Carcinoma AJCC v7
- Avelumab
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Feb 25, 2022
HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1
Recruiting
- HLA-A2 Positive Cells Present
- Refractory Melanoma
- Alpha-type-1 Polarized Dendritic Cells
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Dec 12, 2022
Multiple Sclerosis Trial in Worldwide (Ofatumumab, First line DMT)
Recruiting
- Multiple Sclerosis
- Ofatumumab
- First line DMT
-
Bayonne, Bayonne Cedex, France
- +42 more
Jul 25, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast
Not yet recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Biopsy
- +7 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Feb 23, 2023
Interferon Beta Therapy in Participants With Multiple Sclerosis
Completed
- Multiple Sclerosis, Relapsing-Remitting
- SC Peginterferon beta-1a
- +2 more
-
Göttingen, GermanyResearch Site
Sep 24, 2019
Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
Recruiting
- Multiple Sclerosis
- Diroximel Fumarate
- +8 more
-
Eden Prairie, MinnesotaOptumInsight
Jan 9, 2023
Multiple Sclerosis Trial (Diroximel Fumarate, Avonex, Tysabri)
Not yet recruiting
- Multiple Sclerosis
- Diroximel Fumarate
- +3 more
- (no location specified)
Dec 12, 2022
Bioequivalence Trial in Tempe, Lincoln (efgartigimod PH20 SC as a prefilled syringe presentation, efgartigimod PH20 SC as a vial
Recruiting
- Bioequivalence
- efgartigimod PH20 SC as a prefilled syringe presentation
- efgartigimod PH20 SC as a vial + syringe presentation
-
Tempe, Arizona
- +1 more
Apr 5, 2023
MS (Multiple Sclerosis), Erythema Trial in Kirkland (Warm Compress Before Injection, Cold Compress After Injection)
Completed
- MS (Multiple Sclerosis)
- Erythema
- Warm Compress Before Injection
- Cold Compress After Injection
-
Kirkland, WashingtonEvergreen Health
Mar 10, 2022
Multiple Sclerosis, Relapsing-Remitting Trial in Kocaeli (EK-12, INF beta-1a)
Recruiting
- Multiple Sclerosis, Relapsing-Remitting
- EK-12
- INF beta-1a
-
Kocaeli, TurkeyKocaeli University, Faculty of Medicine, Department of Neurology
Jul 23, 2021
COVID-19, INTERFERON, NEBULIZATION Trial in France (inhaled type I interferon, WFI water nebulization)
Recruiting
- COVID-19
- +2 more
- inhaled type I interferon
- WFI water nebulization
-
Abbeville, France
- +6 more
Jan 3, 2022
Chronic Pulmonary Aspergillosis, Aspergillosis Trial (Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as
Not yet recruiting
- Chronic Pulmonary Aspergillosis
- Aspergillosis
- Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care
- Antifungals as standard of care
- (no location specified)
Dec 13, 2022
Multiple Sclerosis Trial in Worldwide (Interferon beta-1a, Fingolimod, Placebo capsule)
Recruiting
- Multiple Sclerosis
- Interferon beta-1a
- +3 more
-
Birmingham, Alabama
- +106 more
Jan 13, 2023
Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7 Trial in Buffalo (drug,
Completed
- Metastatic Carcinoma in the Liver
- +4 more
- Celecoxib
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Feb 25, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Trial in United States
Suspended
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Cytarabine
- +2 more
-
Los Angeles, California
- +5 more
Dec 10, 2022